Stem cell co Kadimastem expands Merck Serono collaboration – Globes
|
Stem cell co Kadimastem expands Merck Serono collaboration
Globes Stem cell developer Kadimastem(TASE: KDST) has signed a Memorandum of Understanding (MOU) with German pharmaceutical company Merck Serono to expand the two companies’ stem cell based drug screening collaboration which began in April 2012. Companies collaborating on new approach to stem cell-based drug screeningMedCity News |
